{"disease":{"id":"immunologic-disease","name":"immunologic disease"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05780099","title":"Prospective Observational Study to Characterize Patients Treated at Internal Medicine Clinics","phase":"","overall_status":"RECRUITING","enrollment_count":50000,"lead_sponsor_name":"IRCCS San Raffaele","has_results":false},{"nct_id":"NCT01287000","title":"Gulf Long-Term Follow-Up Study","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":32658,"lead_sponsor_name":"National Institute of Environmental Health Sciences (NIEHS)","has_results":false},{"nct_id":"NCT05403151","title":"Controls and Healthy Vasculature Initiative","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"National Heart, Lung, and Blood Institute (NHLBI)","has_results":false},{"nct_id":"NCT00968084","title":"Screening Protocol for Subjects Being Evaluated for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Protocols","phase":"","overall_status":"COMPLETED","enrollment_count":587,"lead_sponsor_name":"National Heart, Lung, and Blood Institute (NHLBI)","has_results":false},{"nct_id":"NCT05807256","title":"Medically Assisted Fertilization Techniques in Systemic Immunoreumatologic Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"IRCCS San Raffaele","has_results":false},{"nct_id":"NCT05425953","title":"Endocrine, Metabolic, Cardiovascular and Immunological Aspects of Sex Chromosome Abnormalities in Relation to Genotype","phase":"","overall_status":"UNKNOWN","enrollment_count":320,"lead_sponsor_name":"University of Aarhus","has_results":false},{"nct_id":"NCT06390748","title":"Esmolol in Sepsis Management:Evaluating Immunomodulatory Effects and Impact on Patient Outcomes","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":150,"lead_sponsor_name":"Lin Chen","has_results":false},{"nct_id":"NCT03225950","title":"Interaction Between Immune Cells and Bacteria Associated With Periodontitis","phase":"","overall_status":"COMPLETED","enrollment_count":90,"lead_sponsor_name":"University of Copenhagen","has_results":false},{"nct_id":"NCT04365101","title":"Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":86,"lead_sponsor_name":"Celularity Incorporated","has_results":false},{"nct_id":"NCT05098691","title":"Early Onset Preeclampsia and Nectin-4","phase":"","overall_status":"COMPLETED","enrollment_count":84,"lead_sponsor_name":"Hatice Akkaya","has_results":false},{"nct_id":"NCT02280902","title":"Incidence and Risk Factors for Infections in Patient Treated With Corticosteroids, Immunosuppressive Drugs or Biotherapy for Immunologic and Inflammatory Diseases","phase":"","overall_status":"COMPLETED","enrollment_count":72,"lead_sponsor_name":"University Hospital, Bordeaux","has_results":false},{"nct_id":"NCT05786235","title":"Patients Pregnant Women With or Without Primary Antiphospholipid Antibody Syndrome","phase":"","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"IRCCS San Raffaele","has_results":false},{"nct_id":"NCT04983030","title":"Safety, Immunogenicity, Efficacy of Ad26.Mos4.HIV, MVA-BN-HIV and PGT121, PGDM1400, and VRC07-523LS in HIV-1-Infected Adults","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":36,"lead_sponsor_name":"Boris Juelg, MD PhD","has_results":false},{"nct_id":"NCT07208058","title":"A Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis (Also Known as Macrophage Activation Syndrome [MAS])","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"TJ Biopharma Co., Ltd.","has_results":false},{"nct_id":"NCT04310592","title":"Natural Killer Cell (CYNK-001) Infusions in Adults with AML","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":27,"lead_sponsor_name":"Celularity Incorporated","has_results":false}],"total":15},"guidelines":[],"source":"Drug Landscape verified database"}